Essais liés6clinical trials
VilleDebrecenlocalisation
PaysHungarylocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05126277

Ouvrir le site du centre

Essais cliniques associés

6
MoléculeIndication / populationPhaseNCTTitreStatut
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL Maladie coronarienne Phase 3 NCT05739383 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. ACTIVE_NOT_RECRUITING
Pelacarsen (TQJ230) Accident vasculaire cérébral Phase 3 NCT07517263 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) ACTIVE_NOT_RECRUITING
VAY736 1ml PFS Lupus Phase 2 NCT06293365 Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease ACTIVE_NOT_RECRUITING
ianalumab s.c. q4w Lupus Phase 3 NCT05126277 SIRIUS-LN — Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis ACTIVE_NOT_RECRUITING
rapcabtagene autoleucel Lupus Phase 2 NCT06581198 A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) ACTIVE_NOT_RECRUITING
Iptacopan (part 1) Lupus Phase 2 NCT05268289 Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V TERMINATED